Rockwell Medical Future Growth

Future criteria checks 4/6

Rockwell Medical is forecast to grow earnings and revenue by 117.6% and 9.5% per annum respectively while EPS is expected to grow by 121.5% per annum.

Key information

117.6%

Earnings growth rate

121.5%

EPS growth rate

Medical Equipment earnings growth	16.4%
Revenue growth rate	9.5%
Future return on equity	n/a
Analyst coverage	Low
Last updated	25 Mar 2024

Recent future growth updates

Recent updates

An Intrinsic Calculation For Rockwell Medical, Inc. (NASDAQ:RMTI) Suggests It's 46% Undervalued

Sep 02

Rockwell Medical Q2 Earnings Preview

Aug 12

Rockwell Medical: Triferic Remains Key Despite Sluggish Growth Profile

Mar 02

Rockwell Medical: Down But By No Means Out

Oct 05

Rockwell Medical pops 6% on licensing deal for Triferic AVNU in Turkey

Jun 08

Health Check: How Prudently Does Rockwell Medical (NASDAQ:RMTI) Use Debt?

Mar 08

Some Rockwell Medical, Inc. (NASDAQ:RMTI) Analysts Just Made A Major Cut To Next Year's Estimates

Feb 10

How Many Rockwell Medical, Inc. (NASDAQ:RMTI) Shares Do Institutions Own?

Jan 18

Dosing underway in Rockwell Medical's late-stage Triferic trial in China

Jan 13

Rockwell Medical: Heavily Oversold Company With Big Potential

Jan 11

This Insider Has Just Sold Shares In Rockwell Medical, Inc. (NASDAQ:RMTI)

Dec 21

Rockwell Medical, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 09

Earnings and Revenue Growth Forecasts

NasdaqCM:RMTI - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	101	2	N/A	N/A	2
12/31/2024	89	-3	N/A	N/A	2
12/31/2023	84	-9	-10	-9	N/A
9/30/2023	81	-9	-10	-10	N/A
6/30/2023	76	-12	-8	-7	N/A
3/31/2023	76	-13	-12	-11	N/A
12/31/2022	73	-19	-17	-17	N/A
9/30/2022	69	-25	-26	-26	N/A
6/30/2022	66	-29	-32	-32	N/A
3/31/2022	63	-32	-31	-31	N/A
12/31/2021	62	-33	-34	-34	N/A
9/30/2021	62	-32	-34	-33	N/A
6/30/2021	61	-32	-32	-31	N/A
3/31/2021	62	-31	-36	-36	N/A
12/31/2020	62	-31	-31	-30	N/A
9/30/2020	63	-30	-27	-26	N/A
6/30/2020	63	-30	-28	-28	N/A
3/31/2020	62	-33	-30	-28	N/A
12/31/2019	61	-34	-29	-27	N/A
9/30/2019	63	-36	-29	-28	N/A
6/30/2019	64	-33	-28	-26	N/A
3/31/2019	64	-35	-22	-21	N/A
12/31/2018	63	-32	-21	-20	N/A
9/30/2018	61	-32	-21	-19	N/A
6/30/2018	59	-32	-20	-19	N/A
3/31/2018	58	-27	-22	-21	N/A
12/31/2017	57	-26	-23	-21	N/A
9/30/2017	56	-22	N/A	-16	N/A
6/30/2017	54	-21	N/A	-18	N/A
3/31/2017	54	-20	N/A	-16	N/A
12/31/2016	53	-20	N/A	-12	N/A
9/30/2016	54	-21	N/A	-16	N/A
6/30/2016	56	-18	N/A	-13	N/A
3/31/2016	55	-16	N/A	-14	N/A
12/31/2015	55	-14	N/A	-13	N/A
9/30/2015	56	-15	N/A	4	N/A
6/30/2015	55	-17	N/A	8	N/A
3/31/2015	55	-17	N/A	11	N/A
12/31/2014	54	-21	N/A	4	N/A
9/30/2014	54	-23	N/A	-21	N/A
6/30/2014	53	-33	N/A	-31	N/A
3/31/2014	53	-41	N/A	-50	N/A
12/31/2013	52	-49	N/A	-51	N/A
9/30/2013	51	-54	N/A	-50	N/A
6/30/2013	51	-59	N/A	-49	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RMTI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: RMTI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RMTI is expected to become profitable in the next 3 years.

Revenue vs Market: RMTI's revenue (9.5% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: RMTI's revenue (9.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RMTI's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Rockwell Medical Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Consensus EPS estimates upgraded to US$0.10 loss, revenue downgraded

Rockwell Medical, Inc. Provides Earnings Guidance for Fourth Quarter and Full-Year 2023

Rockwell Medical, Inc. Provides Financial Guidance for the Year 2023

Forecast to breakeven in 2025

Consensus EPS estimates fall by 23%

Rockwell Medical, Inc. Revises Financial Guidance for the Year 2023

Recent updates

Rockwell Medical, Inc. to Report Q1, 2024 Results on May 14, 2024

Rockwell Medical, Inc., Annual General Meeting, May 21, 2024

Consensus EPS estimates upgraded to US$0.10 loss, revenue downgraded

New minor risk - Share price stability

Full year 2023 earnings: EPS exceeds analyst expectations

Rockwell Medical, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Is Rockwell Medical (NASDAQ:RMTI) A Risky Investment?

Rockwell Medical, Inc. Provides Earnings Guidance for Fourth Quarter and Full-Year 2023

Rockwell Medical, Inc. (NASDAQ:RMTI) Doing What It Can To Lift Shares

New major risk - Financial position

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rockwell Medical, Inc. Provides Financial Guidance for the Year 2023

Rockwell Medical, Inc. Appoints Jesse Neri as Senior Vice President, Finance

Rockwell Medical, Inc. Appoints Joan Lau, Ph.D. to the Company's Board of Directors

Rockwell Medical, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Is Rockwell Medical (NASDAQ:RMTI) Using Too Much Debt?

Forecast to breakeven in 2025

Rockwell Medical, Inc. Announces Resignation of as Senior Vice President, Finance and Chief Accounting Officer

Consensus EPS estimates fall by 23%

Rockwell Medical, Inc. Revises Financial Guidance for the Year 2023

Second quarter 2023 earnings: EPS misses analyst expectations

Consensus estimates of losses per share improve by 15%

Rockwell Medical, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Rockwell Medical, Inc. (NasdaqCM:RMTI) agreed to acquire Substantially All Assets of Evoqua Water Technologies LLC for $16 million.

New major risk - Share price stability

Is Rockwell Medical (NASDAQ:RMTI) Weighed On By Its Debt Load?

Consensus estimates of losses per share improve by 13%

Rockwell Medical, Inc. Provides Revenue Guidance for Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Rockwell Medical, Inc. to Report Q4, 2022 Results on Mar 30, 2023

Price target decreased to US$5.00

Rockwell Medical, Inc. Provides Earnings Guidance for the Full Year 2022

Is There Now An Opportunity In Rockwell Medical, Inc. (NASDAQ:RMTI)?

Rockwell Medical, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Rockwell Medical, Inc. Names Heather Hunter as SVP, Chief Corporate Affairs Officer

An Intrinsic Calculation For Rockwell Medical, Inc. (NASDAQ:RMTI) Suggests It's 46% Undervalued

Consensus estimates of losses per share improve by 24%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Rockwell Medical Q2 Earnings Preview

Rockwell Medical, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Price target decreased to US$19.00

Rockwell Medical, Inc. Provides Clinical Update

Rockwell Medical, Inc. announced that it has received $14.9 million in funding

Rockwell Medical Regains Compliance with Nasdaq Listing Requirements

Rockwell Medical, Inc. Submits Supplemental Data to FDA for IND Application for Phase 2 FPC Home Infusion Trial

Rockwell Medical, Inc. to Report Q1, 2022 Results on May 16, 2022

Rockwell Medical, Inc. Announces Completion of Patient Enrollment Ahead of Schedule in Pivotal Phase 3 Clinical Trial of Triferic(R) in China

Rockwell Medical, Inc. announced delayed annual 10-K filing

Rockwell Medical: Triferic Remains Key Despite Sluggish Growth Profile

Forecast to breakeven in 2023

Price target decreased to US$4.00

Rockwell Medical Receives Important Feedback from FDA on Its IND Application for Phase 2 Trial of Ferric Pyrophosphate Citrate in Home Infusion

Third quarter 2021 earnings released: US$0.081 loss per share (vs US$0.10 loss in 3Q 2020)

Rockwell Medical: Down But By No Means Out

Second quarter 2021 earnings released: US$0.09 loss per share (vs US$0.099 loss in 2Q 2020)

Rockwell Medical Receives Written Notice from the Nasdaq Stock Market

Rockwell Medical pops 6% on licensing deal for Triferic AVNU in Turkey

First quarter 2021 earnings released: US$0.083 loss per share (vs US$0.12 loss in 1Q 2020)

Rockwell Medical, Inc. Announces Marketing Approval of Triferic® AVNU™ in Canada

Rockwell Medical, Inc. to Report Q4, 2020 Results on Mar 31, 2021

Health Check: How Prudently Does Rockwell Medical (NASDAQ:RMTI) Use Debt?

Rockwell Medical Announces U.S. Availability of Triferic AVNU for Replacement of Iron and Maintenance of Hemoglobin in Patients on Hemodialysis

Some Rockwell Medical, Inc. (NASDAQ:RMTI) Analysts Just Made A Major Cut To Next Year's Estimates

New 90-day high: US$1.48

Rockwell Medical, Inc.(NasdaqGM:RMTI) dropped from S&P Healthcare Equipment Select Industry Index

Rockwell Medical, Inc. Announces Termination of Ajay Gupta, M.D. as the Company’s Chief Scientific Officer

How Many Rockwell Medical, Inc. (NASDAQ:RMTI) Shares Do Institutions Own?

New 90-day high: US$1.25